Citation: | CHEN Yiling, FENG Jiangjiang, YANG Haixue, SHI Yaping, LI Longnan, FENG Fang. Determination of genotoxic impurities of alkyl methanesulfonates in methanesulfonic acid by gas chromatography–mass spectrometry[J]. Journal of China Pharmaceutical University, 2020, 51(4): 472-478. DOI: 10.11665/j.issn.1000-5048.20200413 |
[1] |
Glowienke S, Frieauff W, Allmendinger T, et al. Structure-activity considerations and in vitro approaches to assess the genotoxicity of 19 methane-, benzene- and toluenesulfonic acid esters[J]. Mutat Res-Gen Tox En, 2005,581(1/2): 23-34.
|
[2] |
Clapp NK, Craig AW, Toya Sr RE. Oncogenicity by methyl methanesulfonate in male RF mice[J]. Science, 1968, 3844(161): 913-914.
|
[3] |
Pfister T, Chapelon AE. General 4-week toxicity study with EMS in the rat[J]. Toxicol Lett, 2009,190(3):271-285.
|
[4] |
Coffing SL, Kenyon MO, Ackerman JI, et al. Evaluation of the in vivo mutagenicity of isopropyl methanesulfonate in acute and 28‐day studies[J]. Environ Mol Mutagen, 2015, 56(3):322-332.
|
[5] |
European Medicines Agency.
|
[6] |
Center for Drug Evaluation and Research.
|
[7] |
National Medical Products Administration. Technical guidance on genotoxicity testing (药物遗传毒性研究技术指导原则) [EB/OL]. (2018-03-12) [
|
[8] |
Chinese Pharmacopoeia Commision.
|
[9] |
Teasdale A, Eyley SC, Delaney ED, et al. Mechanism and processing parameters affecting the formation of methyl methanesulfonate from methanol and methanesulfonic acid: an illustrative example for sulfonate ester impurity formation[J]. Org Process Res Dev, 2009,13(3):429-433.
|
[10] |
Teasdale A, Delaney EJ, Eyley SC, et al. A detailed study of sulfonate ester formation and solvolysis reaction rates and application toward establishing sulfonate ester control in pharmaceutical manufacturing processes[J]. Org Process Res Dev, 2010, 14(4):999-1007.
|
[11] |
Shen DD, Zhu JL, Wu GF, et al. Development of synthesis of phosphatidylinositol 3-kinases inhibitor puquitinib mesylate [J]. Chin J Org Chem(有机化学), 2019, 39(9):2676-2680.
|
[12] |
Elder D, Facchine KL, Levy JN, et al. An approach to control strategies for sulfonate ester formation in pharmaceutical manufacturing based on recent scientific understanding[J]. Org Process Res Dev, 2012, 16(11):1707-1710.
|
[13] |
Ramjitt HG, Singh MM, Coddington AB, et al. Gas chromatographic/mass spectrometric analysis of methyl methanesulphonate and ethyl methanesulphonate in the bismesylate salt of DPI 201-106, a positive inotropic agent for the treatment of heart failure[J]. J Mass Spectrom, 1996, 31(8): 867-872.
|
[14] |
Zhou J, Xu J, Zheng XY, et al. Determination of methyl methanesulfonate and ethyl methanesulfonate in methanesulfonic acid by derivatization followed by high-performance liquid chromatography with ultraviolet detection[J]. J Sep Sci ,2017,40(17):3414-3421.
|
[15] |
European Directorate for Quality and Medicines&HealthCare (EDQM).
|
[16] |
Zhang CZ, Huang L, Wu ZG, et al. Determination of sulfonate ester genotoxic impurities in imatinib mesylate by gas chromatography with mass spectrometry [J]. J Sep Sci, 2016, 39(18):3558-3563.
|
[17] |
Wollein U, Schramek N. Simultaneous determination of alkyl mesilates and alkyl besilates in finished drug products by direct injection GC/MS[J]. Eur J Pharm Sci, 2012, 45(1/2):201-204.
|
[18] |
Qian C, Gou XL, Hu GH, et al. Determination of residual mesylate esters in lurasidone hydrochloride tablets by GC-MS/SIM[J]. Anal Instru(分析仪器),2018(01):199-203.
|
[1] | YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202 |
[2] | LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901 |
[3] | WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902 |
[4] | YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003 |
[5] | ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403 |
[6] | LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114 |
[7] | FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302 |
[8] | CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203 |
[9] | WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303 |
[10] | TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572. |